Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b extension study of oral edaravone regimens in ALS (MT-1186-A04)
jRCT2071210117Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of edaravone in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Time to 12-point ALSFRS-R decrease or death. Started Feb 2022; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2071210117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210117.